Dr Reddy’s Laboratories Ltd on Tuesday (September 16) announced the launch of tegoprazan, a novel patented molecule for acid-related gastrointestinal diseases, in the Indian market.
The drug will be marketed under the brand name PCAB in a 50 mg dosage form.
Tegoprazan is a next-generation potassium-competitive acid blocker (PCAB) indicated for treating conditions such as erosive and non-erosive gastroesophageal reflux disease (GERD) and gastric ulcers.
The company said the molecule offers a rapid onset of action and sustained gastric pH control, providing potential clinical benefits over existing therapies in acid peptic disease management.
The launch follows Dr Reddy’s exclusive 2022 partnership with South Korea-based HK inno.N Corporation to commercialise tegoprazan in India and select emerging markets.
The drug is already approved in 21 countries, including South Korea and China, and has completed phase-III trials in the US.
Commenting on the development, MV Ramana, CEO of Branded Markets (India & Emerging Markets) at Dr Reddy’s, said the launch underscores the company’s focus on innovation in gastrointestinal care.
“Our partnership with HK inno.N brings complementary strengths to improve patient access to this innovative molecule, which addresses critical gaps in acid peptic disease management,” he said.
Dr Reddy’s already has a strong portfolio in gastrointestinal therapeutics with brands such as Omez®, Razo® and Vono™. The company said tegoprazan further strengthens its presence in the segment.
Also Read: Blue Dart Express arm gets ₹420-crore GST demand
Shares of Dr Reddy’s Laboratories Ltd ended higher on Tuesday (September 16) by 0.79 % at ₹1,311.10 on the NSE.
